CatalystPit
TerminalPit ConsensusInsidersPoliticiansInstitutionsNewsScreener

PRMEPrime Medicine, Inc.

NASDAQ · Biological Products, (No Diagnostic Substances)
Last close $3.06 · 2026-09-30
ABOUT
ExchangeNASDAQ
SectorHealthcare
IndustryBiological Products, (No Diagnostic Substances)
Market cap$554.11M
RECENT INSIDER TRADES
  • 2025-08-05 · GV 2021 GP, L.L.C. (10% Owner) · BUY
  • 2025-08-01 · NELSEN ROBERT (Director) · BUY
  • 2025-08-01 · ARCH Venture Partners X, LLC (10% Owner) · BUY
  • 2025-08-01 · ARCH Venture Partners XII, LLC (10% Owner) · BUY
  • 2025-07-01 · Liu David R. (10% Owner) · BUY
INSTITUTIONAL OWNERSHIP
Institutional holders201
Shares held122,743,118
Value$437.15M
Percent of shares outstanding67.67%
As of quarter end2026-06-30
RECENT NEWS
  • Prime Medicine stock rating maintained at Market Outperform by Citizens
  • Prime Medicine doses first patient in Wilson disease gene therapy trial
  • Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
  • Citizens reiterates Prime Medicine stock rating on gene editing capabilities
  • Prime Medicine stock holds at outperform on FDA IND clearance
CatalystPit
FeaturesComing soonPricingComing soonPrivacyTermsDisclaimerAffiliate TermsContact
2026 CATALYSTPIT · NOT FINANCIAL ADVICE · DELAYED FILINGS
Prime Medicine, Inc. (PRME) · Stock Price, Insider Trades, Institutional Holdings · CatalystPit